PVX-6
/ PapiVax
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 20, 2022
PVX-6: Study of Treatment for HPV16+ ASC-US or LSIL
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: PapiVax Biotech, Inc. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024
Trial completion date • Trial primary completion date • CD8
March 10, 2021
PVX-6: Study of Treatment for HPV16+ ASC-US or LSIL
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: PapiVax Biotech, Inc.; Trial completion date: Dec 2021 ➔ Dec 2023; Trial primary completion date: Jun 2021 ➔ Jun 2023
Clinical • Trial completion date • Trial primary completion date • CD8
March 06, 2020
PVX-6: Study of Treatment for HPV16+ ASC-US or LSIL
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: PapiVax Biotech, Inc.; Initiation date: Jul 2019 ➔ Jul 2020
Clinical • Trial initiation date
1 to 3
Of
3
Go to page
1